Our Platform
Our Platform: Panx1 Channel Blockers
Pannex Therapeutics has a proprietary platform to discover and develop best-in-class Panx1 channel blockers.
Pannex Therapeutics has a proprietary platform to discover and develop best-in-class Panx1 channel blockers.
Our integrated platform combines deep biology, advanced discovery technologies, medicinal chemistry excellence, and translational validation to create differentiated Panx1 channel blockers.
Panx1 is a validated upstream target in chronic neuropathic pain and neuroinflammation.
Structure-enabled discovery using the 3D human Panx1 channel and in-silico design.
Hundreds of molecules designed across multiple chemical classes to optimize drug-like properties.
Integrated research connecting biology, pharmacology and preclinical validation.
In vitro, ex vivo and in vivo validation within a development-focused framework.
Built to deliver differentiated clinical candidates and expand into multiple disease areas.
Designed to deliver differentiated clinical candidates and expand into multiple disease areas with precision and efficiency.